Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

L'Hospitalet de Llobregat-Barcelona, Spain Clinical Trials

A listing of L'Hospitalet de Llobregat-Barcelona, Spain clinical trials actively recruiting patients volunteers.

RESULTS

Found (64) clinical trials

Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA)

Bladder cancer is the 9th most common cancer worldwide, with around 429.800 new cases diagnosed in 2012 and the 5th most common cancer in Europe, with more than 151.000 new cases diagnosed in 2012. Relating mortality figures, bladder cancer is the 13th most common cause of cancer death worldwide, with ...

Phase

0.0 miles

Learn More »

BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)

Hodgkin lymphoma (HL) is a lymphoid neoplasm characterized by the presence of CD30-positive Hodgkin Reed-Sternberg cells in a background of inflammatory cells. The majority of patients with HL have a good outcome with first-line chemotherapy such as ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) or BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine,procarbazine ...

Phase

0.0 miles

Learn More »

REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia

Phase I-II multi-site, exploratory, interventional, unmasked, non-randomized, single arm clinical trial. A single drug will be administered in four different, increasing doses to four consecutive cohorts. The first phase of the study will focus on determining the most effective and tolerated dose of the study drug. The second phase will ...

Phase

0.0 miles

Learn More »

A Study to Determine Dose Safety Tolerability and Efficacy of CC-220 Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma

Subjects assigned to CC-220 monotherapy, who develop progressive disease (PD) will have the option to receive DEX in addition to CC-220 after consultation with the Medical Monitor. The dose of CC-220 will not be higher than the dose of CC-220 used in combination with dexamethasone in Cohort B that has ...

Phase

0.73 miles

Learn More »

IO102 With Pembrolizumab With or Without Chemotherapy as First-line Treatment of Metastatic NSCLC

The purpose of this study is to determine if IO102 combined with pembrolizumab with or without chemotherapy is safe tolerable and effective in the treatment of Non-small Cell Lung Carcinoma (NSCLC). The hypothesis is that IO102 will improve the objective response rate (ORR) in patients with metastatic NSCLC.

Phase

1.07 miles

Learn More »

Virus-specific Activated T Lymphocytes From a Donor in Hematopoietic Progenitor Transplanted Patients

A prospective, multicentre, open-label and uncontrolled phase Ib-II clinical trial in which a total of 20 patients 1 year of age with an allogeneic transplant of hematopoietic progenitors and post-transplant CMV infection will be included. The main objective is to evaluate the safety of the infusion of CMV activated T-lymphocytes ...

Phase

1.23 miles

Learn More »

Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion Into Select Solid Tumors (Cervical)

The trial consists of 2 phases: Phase 1: Dose escalation Phase 2: Expansion in advanced cervical cancer Phase 1: Dose Escalation: The enrollment to the Phase 1 portion of the study is completed. The trial will consist of a 3+3 dose escalation that will evaluate different combination dose levels (CDL) ...

Phase

1.23 miles

Learn More »

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

This study is an open-label Phase 1 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors. Single Agent INCB001158: Patients with advanced/metastatic solid tumors will be enrolled into escalating monotherapy dose cohorts to determine the Recommended Phase 2 Dose ...

Phase

1.23 miles

Learn More »

Phase 1/2 Study of the Highly-selective RET Inhibitor Pralsetinib (BLU-667) in Patients With Thyroid Cancer Non-Small Cell Lung Cancer and Other Advanced Solid Tumors

The study consists of 2 parts, a dose-escalation part (Phase 1) and an expansion part (Phase 2). Both parts will enroll patients with advanced non-resectable NSCLC, advanced non-resectable thyroid cancer and other advanced solid tumors that have progressed following standard systemic therapy, have not adequately responded to standard systemic therapy, ...

Phase

1.23 miles

Learn More »

PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors

The purpose of this first-in-human study of CX-2009 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2009 in adult subjects with metastatic or locally advanced unresectable solid tumors. PROCLAIM: PRObody CLinical Assessment In Man CX-2009 clinical trial 001 PROBODY is a trademark of CytomX ...

Phase

1.23 miles

Learn More »